Outcomes of bilateral implantation of phakic IOLs

Article

Dr Antonio Toso discusses his recent study of 8 patients who received bilateral implantations of the Acrysof Cachet Phakic IOLs. Dr Toso and Dr Morselli described the visual outcomes and the aberrometry of this study at the 2010 ESCRS meeting in Paris.

It has been previously reported by Drs Marco and Giuseppe Lombardo that analysis of wavefront aberrations can be used in determining the optical quality and visual performance of the eye.1 On reading this study Dr Antonio Toso of the St Bassiano Hospital in Bassano del Grappa, Italy, realised that young, highly myopic patients suffer from poor distance vision, mainly in mesopic conditions. This is a result of positive spherical aberration, which becomes the dominant high order aberration in degrading optical quality when the pupils dilate. Dr Toso decided that he would like to understand whether the AcrySof Cachet phakic IOL (pIOL) from Alcon Laboratories would be able to provide a better quality of distance vision.

In collaboration with Dr Simonetta Morselli, Dr Toso examined the visual outcomes and aberrometry in a group of eight patients who had undergone bilateral implantation with the Acrysof Cachet pIOL. The results of this study were presented at the 2010 ESCRS Meeting held in Paris.

Lens selection

Dr Toso revealed that the lens was very easy to implant and he explained: "The design and softness of the haptics do not cause pupil ovalisation and conform to the shape of the angle very well." Additionally, he found it beneficial that the lens has been made of the same soft and flexible hydrophobic acrylic material as the other AcrySof IOLs. "Besides all of this, the water-tight corneal incision (no more than 2.6 mm) and not being required to perform peripheral iridotomy, convinced me of the advantages of this lens," he continued.

Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.